Literature DB >> 16421692

Is dual defibrillator better than conventional DDD pacing in brady-tachy syndrome? Results of the ICARUS Trial (Internal Cardioversion Antitachypacing and Prevention: Resource Utilization Study).

Massimo Santini1, Renato Ricci, Carlo Pignalberi, Maurizio Russo, Barbara Magris, Nicoletta Grovale, Tiziana De Santo.   

Abstract

AIM OF THE STUDY: To compare the impact of dual defibrillator versus conventional DDD pacing on quality of life and hospitalizations in patients with sinus node disease and recurrent symptomatic atrial fibrillation. STUDY
DESIGN: Prospective, parallel, controlled trial.
METHODS: Sixty-three patients (41 M, mean age 71 +/- 8 years) with sinus node disease and at least three symptomatic episodes of atrial fibrillation during the last year were enrolled. Thirty-one consecutive patients received a dual defibrillator (group A) and 32 standard DDD pacing (group B). In group A, 12 patients received an external remote-control device in order to shock themselves in case of atrial fibrillation, while 19 were scheduled for early in-hospital manual shock. Seventy-five percent had been hospitalized during the last year and 57% had required electrical cardioversion. Atrial fibrillation was persistent in 63.5% and paroxysmal in 37.5%. The follow-up lasted 1 year.
RESULTS: Atrial fibrillation recurred in 83.3% in group A and 79.3% in group B (p = ns). Electrical cardioversion was applied in 54.8% in group A and in 21.9% in group B (p < 0.05). On the whole, 89.5% of electrical cardioversions were delivered in the defibrillator group (p < 0.0001). In the whole population 27.0% patients had cardiac-related hospitalization (31.2% in the pacemaker group and 22.6% in the defibrillator group, p = n.s.). In patients with persistent atrial fibrillation, cardiac-related hospitalization rate was significantly lower in the group A (0% vs. 30%, p < 0.05). Considering Symptom Check List, symptoms significantly improved in the whole population, but symptom number and frequency improved significantly only in the group A. Similarly, SF-36 questionnaire scores showed a little higher quality of life improvement in the group A.
CONCLUSIONS: Dual defibrillator showed consistent trends toward a higher effectiveness when compared with standard DDD pacing. Dual defibrillator was associated to reduced in-patient cardioversions and to better quality of life. All-cause hospitalizations were reduced only in patients with persistent atrial fibrillation.

Entities:  

Mesh:

Year:  2006        PMID: 16421692     DOI: 10.1007/s10840-006-6204-3

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  39 in total

Review 1.  Deleterious effects of long-term single-chamber ventricular pacing in patients with sick sinus syndrome: the hidden benefits of dual-chamber pacing.

Authors:  A B Hesselson; V Parsonnet; A D Bernstein; G J Bonavita
Journal:  J Am Coll Cardiol       Date:  1992-06       Impact factor: 24.094

2.  Determinants of efficacy of atrial pacing in preventing atrial fibrillation recurrences.

Authors:  G Stabile; G Senatore; A De Simone; P Turco; F Coltorti; P Nocerino; D F Vitale; M Chiariello
Journal:  J Cardiovasc Electrophysiol       Date:  1999-01

3.  Influence of cardiac pacing mode on the long-term development of atrial fibrillation.

Authors:  J M Feuer; A H Shandling; J C Messenger
Journal:  Am J Cardiol       Date:  1989-12-01       Impact factor: 2.778

4.  Spontaneous episodes of atrial fibrillation after implantation of the Metrix Atrioverter: observations on treated and nontreated episodes. Metrix Investigators.

Authors:  C Timmermans; S Lévy; G M Ayers; W Jung; L Jordaens; M Rosenqvist; B Thibault; J Camm; L M Rodriguez; H J Wellens
Journal:  J Am Coll Cardiol       Date:  2000-05       Impact factor: 24.094

5.  Long-term haemodynamic and antiarrhythmic benefits of DDIR versus DDI pacing mode in sick sinus syndrome and chronotropic incompetence.

Authors:  M Santini; R Ricci; A Puglisi; S Mangiameli; A Proclemer; C Menozzi; G De Fabrizio; G Leoni; F Lisi; F De Seta
Journal:  G Ital Cardiol       Date:  1997-09

6.  Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias.

Authors:  M R Gold; N Sulke; D S Schwartzman; R Mehra; D E Euler
Journal:  J Cardiovasc Electrophysiol       Date:  2001-11

7.  Effect of the implantable atrial defibrillator on the natural history of atrial fibrillation.

Authors:  H F Tse; C P Lau; C M Yu; K L Lee; G F Michaud; B P Knight; F Morady; S A Strickberger
Journal:  J Cardiovasc Electrophysiol       Date:  1999-09

8.  Improving the acceptability of the atrial defibrillator: patient-activated cardioversion versus automatic night cardioversion with and without sedation (ADSAS 2).

Authors:  Lana Boodhoo; Andrew Mitchell; Michael Ujhelyi; Neil Sulke
Journal:  Pacing Clin Electrophysiol       Date:  2004-07       Impact factor: 1.976

9.  Dual defibrillator improves quality of life and decreases hospitalizations in patients with drug refractory atrial fibrillation.

Authors:  Renato Ricci; Aurelio Quesada; Carlo Pignalberi; Josè Roda; Marcello Disertori; Alessandro Capucci; Antonio Raviele; Massimo Santini
Journal:  J Interv Card Electrophysiol       Date:  2004-02       Impact factor: 1.900

Review 10.  The results of pacing trials for the prevention and termination of atrial tachyarrhythmias: is there any evidence of therapeutic breakthrough?

Authors:  Irina Savelieva; A John Camm
Journal:  J Interv Card Electrophysiol       Date:  2003-04       Impact factor: 1.900

View more
  2 in total

1.  [Sandwiched between the single- and triple-chamber ICD: do we still need the dual-chamber ICD?].

Authors:  C W Israel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2008-12

Review 2.  The worldwide social burden of atrial fibrillation: what should be done and where do we go?

Authors:  Massimo Santini; Renato P Ricci
Journal:  J Interv Card Electrophysiol       Date:  2007-03-20       Impact factor: 1.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.